Clinical Trial Update: Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study evaluating investigational bispecific antibodies in adults with lupus nephritis. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• Bispecific antibodies (investigational)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Lupus Nephritis (LN) | Phase 1 | Status: RECRUITING